EPHX2 and familial dilated cardiomyopathy: Therefore, both stimulating the release of membrane-bound EpFAs in conjunction with sEH enzymatic activity inhibition represents a viable approach to exploit the compensatory increase in CYP2J2 metabolic activity and delay the degradation of the protective EpFAs produced in the DCM heart.